Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01067573 · ClinicalTrials.gov registry record

The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

A clinical trial of Multiple Sclerosis, sponsored by University of South Florida.

Completed
Registry status
20
Enrollment target
1
Study location

NCT01067573 is a study of Multiple Sclerosis that has completed, run by University of South Florida. The registered enrollment target is 20 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01067573, a study of Multiple Sclerosis, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

To determine a correlation between serum leptin levels, nitric oxide preceding a relapse and change in leptin and nitric oxide levels during exacerbation in relapsing remitting multiple sclerosis patients.

Conditions Studied

Study Locations (1)

Florida

  • USF Health - Tampa

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2009-12
Est. Completion 2011-07

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT01067573

The ClinicalTrials.gov registry entry for NCT01067573 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT01067573 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01067573 about?

NCT01067573 is a clinical study titled "The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment". To determine a correlation between serum leptin levels, nitric oxide preceding a relapse and change in leptin and nitric oxide levels during exacerbation in relapsing remitting multiple sclerosis patients.

What is the current status of trial NCT01067573?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2009-12. Estimated completion is 2011-07.

What conditions does trial NCT01067573 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT01067573?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01067573 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.